CN1517120A - Anti-neoplastic medicine and its preparation method - Google Patents
Anti-neoplastic medicine and its preparation method Download PDFInfo
- Publication number
- CN1517120A CN1517120A CNA2003101011541A CN200310101154A CN1517120A CN 1517120 A CN1517120 A CN 1517120A CN A2003101011541 A CNA2003101011541 A CN A2003101011541A CN 200310101154 A CN200310101154 A CN 200310101154A CN 1517120 A CN1517120 A CN 1517120A
- Authority
- CN
- China
- Prior art keywords
- standby
- supernatant
- aspongopus
- cordyceps
- pulverize
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 46
- 230000000118 anti-neoplastic effect Effects 0.000 title abstract 2
- 238000002360 preparation method Methods 0.000 title description 9
- 229940034982 antineoplastic agent Drugs 0.000 title description 4
- 241000660877 Coridius Species 0.000 claims abstract description 25
- 238000000034 method Methods 0.000 claims abstract description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 48
- 239000000843 powder Substances 0.000 claims description 48
- 239000006228 supernatant Substances 0.000 claims description 28
- 239000000203 mixture Substances 0.000 claims description 24
- 241000190633 Cordyceps Species 0.000 claims description 20
- 239000002246 antineoplastic agent Substances 0.000 claims description 18
- 241000628997 Flos Species 0.000 claims description 15
- 229940041181 antineoplastic drug Drugs 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 238000002156 mixing Methods 0.000 claims description 13
- 239000012141 concentrate Substances 0.000 claims description 12
- 238000001035 drying Methods 0.000 claims description 12
- 238000002481 ethanol extraction Methods 0.000 claims description 12
- -1 and filter Substances 0.000 claims description 10
- 230000000259 anti-tumor effect Effects 0.000 claims description 10
- 239000002552 dosage form Substances 0.000 claims description 10
- 239000002994 raw material Substances 0.000 claims description 9
- 235000014375 Curcuma Nutrition 0.000 claims description 4
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims description 4
- 241000407170 Curcuma Species 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 abstract description 7
- 239000000463 material Substances 0.000 abstract description 2
- 235000003392 Curcuma domestica Nutrition 0.000 abstract 1
- 244000008991 Curcuma longa Species 0.000 abstract 1
- 241000233866 Fungi Species 0.000 abstract 1
- 240000001307 Myosotis scorpioides Species 0.000 abstract 1
- 235000003373 curcuma longa Nutrition 0.000 abstract 1
- 235000013976 turmeric Nutrition 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 description 16
- 241000699670 Mus sp. Species 0.000 description 12
- 229940079593 drug Drugs 0.000 description 11
- 239000013641 positive control Substances 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 239000007864 aqueous solution Substances 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 230000005907 cancer growth Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 3
- 240000002853 Nelumbo nucifera Species 0.000 description 3
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 3
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 3
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 3
- 210000003679 cervix uteri Anatomy 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 201000006585 gastric adenocarcinoma Diseases 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 206010041823 squamous cell carcinoma Diseases 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 3
- 229960004528 vincristine Drugs 0.000 description 3
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 3
- 244000164480 Curcuma aromatica Species 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- LAZPBGZRMVRFKY-HNCPQSOCSA-N Levamisole hydrochloride Chemical compound Cl.C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 LAZPBGZRMVRFKY-HNCPQSOCSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 229960003734 levamisole hydrochloride Drugs 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- QGZCUOLOTMJILH-UHFFFAOYSA-N 2h-tetrazol-2-ium;bromide Chemical compound [Br-].C1=N[NH+]=NN1 QGZCUOLOTMJILH-UHFFFAOYSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010064390 Tumour invasion Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001644 anti-hepatocarcinoma Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000009400 cancer invasion Effects 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000004279 orbit Anatomy 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000002229 urogenital system Anatomy 0.000 description 1
- 239000009306 yunnan baiyao Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
An antineoplastic Chinese medicine especially for treating cancers is prepared from 5 Chinese-medicinal materials including asafetide, aspongopus, Chinese caterpillar fungus, turmeric, etc. Its preparing process is also disclosed.
Description
Technical field
The present invention relates to a kind of with natural plant crude drugs be main medicinal ingredient have the antitumor especially medicine of malignant tumor and a preparation method of this medicine thereof.
Technical background
(tumor neoplasm) is a class commonly encountered diseases, frequently-occurring disease to tumor, and wherein malignant tumor (malignanttumor) is the most serious class disease of present harm humans health.The etiology of these tumors, pathogenesis and control thereof are the emphasis of this area research.
Because the pathogenesis of malignant tumor and the cause of disease are not understood as yet fully, thereby lack basic preventive measure.Therefore, the mankind still can't cure malignant tumor as other common frdquently encountered diseases of treatment up to now.Can only treat malignant tumor with palliative method, in the hope of obtaining life quality and longer life cycle preferably.
Because malignant tumor is intractable, since number century, the various countries scholar removes by the improvement operation, seeks to improve outside the approach of chemicotherapy curative effect, seeks valuable clue from traditional medicine, increases treatment means and has become a kind of important channel of conquering malignant tumor.The comprehensive study of Chinese medicine and ethnic drug preparation is that treatment and prevention of tumour circle is sought one of intractable effective ways of solution malignant tumor always.
Summary of the invention
The objective of the invention is to propose one group of antitumor drug that various malignant tumor is had better therapeutical effect.
Another object of the present invention provides this group preparing anti-tumor medicine method.
Antitumor drug of the present invention is the medicament of being made by the following weight proportion raw material: Resina Ferulae 7-13, Aspongopus 11-18, Cordyceps 1-4, Fructus Chebulae 10-15, Rhizoma Curcumae Longae 8-25.
Antitumor drug of the present invention is the medicament of being made by the following weight proportion raw material: Resina Ferulae 7-13, Aspongopus 11-18, Cordyceps 1-4, Fructus Chebulae 10-15, Rhizoma Curcumae Longae 8-25, Flos Caryophylli 7-13.
Antitumor drug of the present invention is the medicament of being made by the following weight proportion raw material: Resina Ferulae 7-13, Aspongopus 11-18, Cordyceps 1-4, Fructus Chebulae 10-15, Rhizoma Curcumae Longae 8-25, Flos Caryophylli 7-13, Radix Et Rhizoma Rhei 1-25.
Antitumor drug of the present invention is the medicament of being made by the following weight proportion raw material: Resina Ferulae 7-13, Aspongopus 11-18, Cordyceps 1-4, Fructus Chebulae 10-15, Rhizoma Curcumae Longae 8-25, Flos Caryophylli 7-13, Radix Et Rhizoma Rhei 1-25, Radix Aucklandiae 7-13.
Technical scheme of the present invention is based on Tibetanmedicine in the Chinese medicine to the understanding and the Therapeutic Principle of tumor invasion mechanism, with reference to the modern pharmacology achievement in research, what filter out from motherland's medical treasure-house has a strengthening vital QI to eliminate pathogenic factors, hard masses softening and resolving, the detoxifcation conditioning, the natural medicinal plant of nourishing Baconic function.The present invention be one group according to the theoretical prescription of Tibetan medicine, and, extract its active ingredient, the preparation of the taking convenience that develops according to the nature and flavor characteristics of each herbal medicine.
Medicine of the present invention is mainly used in the treatment to malignant tumor of digestive tract, malignant tumor of lung, malignant breast tumor, genito-urinary system malignant tumor, head-neck malignant tumor, blood system malignant tumor, lymphsystem malignant tumor, and other malignant tumor is had the auxiliary treatment effect.
Pharmaceutical dosage form of the present invention is a said peroral dosage form on the pharmaceutics.Can be the capsule made through conventional technology of raw material of the present invention and corresponding medicinal adjuvant, tablet, granule, pill etc.Its consumption is per day for adults 2-6 gram.
Preparing anti-tumor medicine method of the present invention is made up of following steps:
One, get Aspongopus and pulverize, use ethanol extraction, it is standby to get supernatant;
Two, get Resina Ferulae and the 30-70% curcuma powder is broken into fine powder, Cordyceps is ground into fine powder, and is with the abundant mixing of aforementioned medicated powder, standby;
Three, Fructus Chebulae and remaining component decoct with water, and filter, concentrate, and add ethanol, leave standstill, and get supernatant and mix with (one), reclaim ethanol and get extractum, with (two) mix homogeneously, drying, pulverize, and make required dosage form.
Preparing anti-tumor medicine method of the present invention is made up of following steps:
One, get Aspongopus and pulverize, use ethanol extraction, it is standby to get supernatant;
Two, get Resina Ferulae, Flos Caryophylli and 30-70% curcuma powder and be broken into fine powder, Cordyceps is ground into fine powder, and is with the abundant mixing of aforementioned medicated powder, standby;
Three, Fructus Chebulae and remaining component decoct with water, and filter, concentrate, and add ethanol, leave standstill, and get supernatant and mix with (one), reclaim ethanol and get extractum, with (two) mix homogeneously, drying, pulverize, and make required dosage form.
Preparing anti-tumor medicine method of the present invention is made up of following steps:
One, get Aspongopus and pulverize, use ethanol extraction, it is standby to get supernatant;
Two, get Resina Ferulae, Flos Caryophylli and 30-70% Rhizoma Curcumae Longae, the 30-70% Radix Et Rhizoma Rhei powder is broken into fine powder, Cordyceps is ground into fine powder, and is with the abundant mixing of aforementioned medicated powder, standby;
Three, Fructus Chebulae and remaining component decoct with water, and filter, concentrate, and add ethanol, leave standstill, and get supernatant and mix with (one), reclaim ethanol and get extractum, with (two) mix homogeneously, drying, pulverize, and make required dosage form.
Preparing anti-tumor medicine method of the present invention is made up of following steps:
One, get Aspongopus and pulverize, use ethanol extraction, it is standby to get supernatant;
Two, get Resina Ferulae, Flos Caryophylli, the Radix Aucklandiae and 30-70% Rhizoma Curcumae Longae, the 30-70% Radix Et Rhizoma Rhei powder is broken into fine powder, Cordyceps is ground into fine powder, and is with the abundant mixing of aforementioned medicated powder, standby;
Three, Fructus Chebulae and remaining component decoct with water, and filter, concentrate, and add ethanol, leave standstill, and get supernatant and mix with (one), reclaim ethanol and get extractum, with (two) mix homogeneously, drying, pulverize, and make required dosage form.
Pharmacodynamics test of the present invention:
One, the external pharmacodynamics examining report of this drug solution
Censorship unit: Yunnan Mingyang Pharmaceutical Co., Ltd.
Censorship medicine: this antitumor drug aqueous solution
Testing goal: detect the inhibition lethal effect of this antineoplastic agent aqueous solution to the In vitro culture growth of cancer cells.
Accept inspection cancerous cell kind: adenocarcinoma of lung (GLC-82), oral squamous cell carcinomas cell (KB), squamous carcinoma of the cervix (Hela), adenocarcinoma of stomach (SGC-7901), hepatocarcinoma (BEL-7402).Enzyme-linked immunosorbent assay instrument: Britain produces WELLSCAN MK3
The positive control vincristine: Hualian Pharmaceutical Co., Ltd., Shanghai produces, lot number 991102 detection methods: tetrazolium bromide (MTT) colorimetry; Get above-mentioned 5 kinds of cancerous cell 2 * 10 respectively
4/ ml cell suspension is inoculated 96 orifice plates, and every hole plantation 0.1ml puts 37 ℃ of CO
2Incubator 24 hours after medicine, positive control, negative control, blank 0.1ml are examined in adding respectively, is placed 37 ℃ of CO again
2Incubator 48 hours, every hole adds MTT solution (5mg/ml) 20 μ l, continues to hatch promptly to stop in 4 hours cultivating, the reject culture fluid, add dimethyl sulfoxide (DMSO) 0.1ml/ hole, make the abundant mixing of solution, on 570nm wavelength enzyme-linked immunosorbent assay instrument, measure each hole absorbance value (OD value).Suppression ratio=(1-dosing group OD value/matched group OD value) * 100%.
Conclusion:
The every hole 0.1mg of this medicine drug level is to the inhibition kill rate average out to 55% of adenocarcinoma of lung GLC, oral squamous cell carcinomas cell KB, squamous carcinoma of the cervix Hela, adenocarcinoma of stomach SGC, hepatocarcinoma BEL growth of cancer cells, the every hole 0.1mg of positive control vincristine is to the inhibition kill rate average out to 74% of above-mentioned 5 kinds of growth of cancer cells, this antitumor drug of Isodose aqueous solution to the inhibition kill rate of above-mentioned 5 kinds of growth of cancer cells than positive control vincristine low 19%.Experiment shows that this antineoplastic agent aqueous solution all has the obvious suppression lethal effect to body place cultivation lung adenocarcinoma cell (GLC-82), oral squamous cell carcinomas cell (KB), squamous carcinoma of the cervix cell (Hela), adenocarcinoma of stomach cell (SGC-7901), the growth of hepatocarcinoma (BEL-7402) cell.
Two, the netted interior multisystem of mice is engulfed the influence of the ability of cleaning up
1, experiment material
Animal: mice, ICR body weight 18-22g, male and female half and half provide the quality certification by the experiment of Yunnan Province's natural drug pharmacology emphasis: the real animal in Yunnan is demonstrate,proved No. 9806.
Medicine: this antitumor drug, lot number 2000702, the 0.5g/ grain is equivalent to crude drug 1g, is provided by Yunnan Mingyang Pharmaceutical Co., Ltd., and the concentration that is made into 1.875%, 3.75%, 5.625% (W/V) with water is for using.Levamisole hydrochloride tablets, lot number 2000503, the 25mg/ sheet, Shiyan Ji core hall pharmaceutical factory product, the concentration that is made into 0.5g with water is for using.The Parker ink, lot number 20000710, the 57ml/ bottle, Shanghai Gillette company limited product supplies to use with sodium chloride injection 1-5 dilution back.
Instrument: day island proper Tianjin UV-2100 spectrophotometer
2, experimental technique and result
50 of mices are divided into 5 groups at random, and 10 every group, male and female half and half.If blank group (C), feedwater; The basic, normal, high dosage group of this antitumor drug (L, M, H) is given this antineoplastic agent medicinal liquid of 1.875%, 3.75%, 5.625%, and positive controls (S) is to the levamisole hydrochloride tablets medicinal liquid of 0.5g.Each group is all by 20ml/kg (jg) administration, once a day, continuous 10 days, 30min after the last administration, tail vein injection Parker ink (supplying to use) 0.1ml/10g body weight with NS-1-5 dilution back, 1min, 5min get blood 20ml from the eye socket rear vein beard respectively with suction pipe (use in advance heparin solution moistening) behind injecting ink, being dissolved in 2ml, the 0.1%Na2Co3 solution, shaking up the wavelength in 580nm, is blank with 0.1%Na2Co3 solution, measure optical density (OD), calculate and clean up index K.
3, conclusion
This antitumor drug 0.375g/kg, 0.75g/kg and 1.125/kg (be relevant to clinical human dosage 5 times, 10 times and 15 times) all can make the K value significantly improve (P＜0.05, P＜0.01 and P＜0.001), show that this medicine can improve the netted interior multisystem of mice and engulf the ability of cleaning up, have the effect of human body immunity improving function.
Three, laboratory report in anti-hepatocarcinoma (H22) the ascitic type mice body
Medicament sources: this medicine is provided by Yunnan Mingyang Pharmaceutical Co., Ltd., is mixed with 2% aqueous solution, and water proof boiled 1 hour, and it is standby to put 4 ℃ of refrigerators.Positive control drug fluorouracil (5-Fu) injection, the general Pharma Inc. in the rising sun East Sea, Shanghai produces lot number 010306.
Laboratory animal: the ICR mice is provided by animal housing of YUNNAN BAIYAO group company.
Tumor strain source: rat liver cancer (H
22) ascitic type introduced by institute of oncology, Beijing.
Experimental technique: abdominal cavity injection inoculation hepatocarcinoma (H under aseptic condition
22) ascitic type cell suspension 8 * 10
6/ 0.2ml/ is only in the ICR mice, and every batch of experiment is provided with three groups and is respectively this medicine medicine group, positive control drug fluorouracil group, negative control normal saline group.Every batch of experiment is with sex ♂ mice, and the laboratory mice average weight is 20g ± 1g random packet numbering, weighs, and begin gastric infusion respectively next day behind the inoculation cancerous cell, and once a day, 10 days is a course of treatment.
Increase in life span calculates by following formula, the survival natural law * % of the survival natural law/matched group of the survival natural law-matched group of increase in life span %=administration group
Experimental summary: experimental result shows that positive control drug fluorouracil group has higher rate elongation, three batches of experimental result average out to 73.1% to the life of lotus (H22) mice.But toxic reaction, mouse death rate reaches 20.0%, 10.0%, 10.0% in the drug delivery regimen.And this liquid medicine decoct is to lotus (H22) mice increase in life span, and three batches of empirical averages are 51.6%, and do not have toxic reaction, do not have the dead mouse phenomenon in the drug delivery regimen, compare P＜0.05 with negative normal saline matched group, and there were significant differences.Show that this liquid medicine decoct has higher rate elongation to the life of lotus (H22) mice.
The specific embodiment
Embodiment 1:
Get Aspongopus 16 grams and pulverize, use 60% ethanol extraction, it is standby to get supernatant; Get Resina Ferulae 8 gram and Rhizoma Curcumae Longae 8 grams are ground into fine powder, Cordyceps 4 grams are ground into fine powder, and are with the abundant mixing of aforementioned medicated powder, standby; Get Fructus Chebulae's 15 grams and decoct with water, filter, concentrate, add ethanol, leave standstill with remaining Rhizoma Curcumae Longae 12 grams, get supernatant and mix, reclaim ethanol and get extractum, with standby medicated powder mix homogeneously with the Aspongopus supernatant, drying is pulverized, and makes tablet according to the conventional tablet preparation method.
Embodiment 2:
Get Aspongopus 18 grams and pulverize, use 65% ethanol extraction, it is standby to get supernatant; Get Resina Ferulae 12 gram and Rhizoma Curcumae Longae 12 grams are ground into fine powder, Cordyceps 3 grams are ground into fine powder, and are with the abundant mixing of aforementioned medicated powder, standby; Fructus Chebulae's 14 grams decoct with water with Flos Caryophylli 9 grams and residue Rhizoma Curcumae Longae 9 grams, filter, concentrate, and add ethanol, leave standstill, get supernatant and mix, reclaim ethanol and get extractum, with standby medicated powder mix homogeneously with the Aspongopus supernatant, drying is pulverized, and makes capsule according to the conventional tablet preparation method.
Embodiment 3:
Get Aspongopus 14 grams and pulverize, use 70% ethanol extraction, it is standby to get supernatant; Get Resina Ferulae 9 gram, Flos Caryophylli 8 grams and Rhizoma Curcumae Longae 13 grams, Radix Et Rhizoma Rhei 13 grams are ground into fine powder, Cordyceps 2 grams are ground into fine powder, and are with the abundant mixing of aforementioned medicated powder, standby; Fructus Chebulae's 14 grams decoct with water with remaining Rhizoma Curcumae Longae 11 grams, Radix Et Rhizoma Rhei 12 grams, filter, concentrate, and add ethanol, leave standstill, get supernatant and mix, reclaim ethanol and get extractum, with standby medicated powder mix homogeneously with the Aspongopus supernatant, drying is pulverized, and makes granule according to the conventional tablet preparation method.
Embodiment 4:
Get Aspongopus 15 grams and pulverize, use 75% ethanol extraction, it is standby to get supernatant; Get Resina Ferulae 10 gram, Flos Caryophylli 10 grams, the Radix Aucklandiae 10 grams and Rhizoma Curcumae Longae 10 grams, Radix Et Rhizoma Rhei 10 grams are ground into fine powder, Cordyceps 2 grams are ground into fine powder, and are with the abundant mixing of aforementioned medicated powder, standby; Fructus Chebulae's 15 grams decoct with water with remaining Rhizoma Curcumae Longae 10 grams, Radix Et Rhizoma Rhei 10 grams, filter, concentrate, and add ethanol, leave standstill, get supernatant and mix, reclaim ethanol and get extractum, with standby medicated powder mix homogeneously with the Aspongopus supernatant, drying is pulverized, and makes pill according to the conventional tablet preparation method.
Claims (8)
1, a kind of antitumor drug is characterized in that it being the medicament of being made by the following weight proportion raw material: Resina Ferulae 7-13, Aspongopus 11-18, Cordyceps 1-4, Fructus Chebulae 10-15, Rhizoma Curcumae Longae 8-25.
2, a kind of antitumor drug is characterized in that it being the medicament of being made by the following weight proportion raw material: Resina Ferulae 7-13, Aspongopus 11-18, Cordyceps 1-4, Fructus Chebulae 10-15, Rhizoma Curcumae Longae 8-25, Flos Caryophylli 7-13.
3, a kind of antitumor drug is characterized in that it being the medicament of being made by the following weight proportion raw material: Resina Ferulae 7-13, Aspongopus 11-18, Cordyceps 1-4, Fructus Chebulae 10-15, Rhizoma Curcumae Longae 8-25, Flos Caryophylli 7-13, Radix Et Rhizoma Rhei 1-25.
4, a kind of antitumor drug is characterized in that it being the medicament of being made by the following weight proportion raw material: Resina Ferulae 7-13, Aspongopus 11-18, Cordyceps 1-4, Fructus Chebulae 10-15, Rhizoma Curcumae Longae 8-25, Flos Caryophylli 7-13, Radix Et Rhizoma Rhei 1-25, Radix Aucklandiae 7-13.
5, according to the described preparing anti-tumor medicine method of claim 1, it is characterized in that forming by following steps:
One, get Aspongopus and pulverize, use ethanol extraction, it is standby to get supernatant;
Two, get Resina Ferulae and the 30-70% curcuma powder is broken into fine powder, Cordyceps is ground into fine powder, and is with the abundant mixing of aforementioned medicated powder, standby;
Three, Fructus Chebulae and remaining component decoct with water, and filter, concentrate, and add ethanol, leave standstill, and get supernatant and mix with (one), reclaim ethanol and get extractum, with (two) mix homogeneously, drying, pulverize, and make required dosage form.
6, according to the described preparing anti-tumor medicine method of claim 2, it is characterized in that forming by following steps:
One, get Aspongopus and pulverize, use ethanol extraction, it is standby to get supernatant;
Two, get Resina Ferulae, Flos Caryophylli and 30-70% curcuma powder and be broken into fine powder, Cordyceps is ground into fine powder, and is with the abundant mixing of aforementioned medicated powder, standby;
Three, Fructus Chebulae and remaining component decoct with water, and filter, concentrate, and add ethanol, leave standstill, and get supernatant and mix with (one), reclaim ethanol and get extractum, with (two) mix homogeneously, drying, pulverize, and make required dosage form.
7, according to the described preparing anti-tumor medicine method of claim 3, it is characterized in that forming by following steps:
One, get Aspongopus and pulverize, use ethanol extraction, it is standby to get supernatant;
Two, get Resina Ferulae, Flos Caryophylli and 30-70% Rhizoma Curcumae Longae, the 30-70% Radix Et Rhizoma Rhei powder is broken into fine powder, Cordyceps is ground into fine powder, and is with the abundant mixing of aforementioned medicated powder, standby:
Three, Fructus Chebulae and remaining component decoct with water, and filter, concentrate, and add ethanol, leave standstill, and get supernatant and mix with (one), reclaim ethanol and get extractum, with (two) mix homogeneously, drying, pulverize, and make required dosage form.
8, according to the described preparing anti-tumor medicine method of claim 4, it is characterized in that forming by following steps:
One, get Aspongopus and pulverize, use ethanol extraction, it is standby to get supernatant;
Two, get Resina Ferulae, Flos Caryophylli, the Radix Aucklandiae and 30-70% Rhizoma Curcumae Longae, the 30-70% Radix Et Rhizoma Rhei powder is broken into fine powder, Cordyceps is ground into fine powder, and is with the abundant mixing of aforementioned medicated powder, standby;
Three, Fructus Chebulae and remaining component decoct with water, and filter, concentrate, and add ethanol, leave standstill, and get supernatant and mix with (one), reclaim ethanol and get extractum, with (two) mix homogeneously, drying, pulverize, and make required dosage form.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2003101011541A CN1190233C (en) | 2003-10-19 | 2003-10-19 | Anti-neoplastic medicine and its preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2003101011541A CN1190233C (en) | 2003-10-19 | 2003-10-19 | Anti-neoplastic medicine and its preparation method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1517120A true CN1517120A (en) | 2004-08-04 |
| CN1190233C CN1190233C (en) | 2005-02-23 |
Family
ID=34304183
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2003101011541A Expired - Lifetime CN1190233C (en) | 2003-10-19 | 2003-10-19 | Anti-neoplastic medicine and its preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1190233C (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102836392A (en) * | 2012-09-28 | 2012-12-26 | 云南名扬药业有限公司 | Liquid oral preparation for treating malignant tumor and preparation method |
| CN103263474A (en) * | 2013-04-16 | 2013-08-28 | 阚兆云 | Traditional Chinese medicine composition and preparation method thereof |
| CN104758822A (en) * | 2015-03-23 | 2015-07-08 | 陈泽林 | A traditional Chinese medicine composition for stomach cancer and a preparing method thereof |
| CN113209251A (en) * | 2021-05-27 | 2021-08-06 | 丁殿西 | Traditional Chinese medicine composition, preparation method and application of traditional Chinese medicine composition in preparation of antitumor drugs |
-
2003
- 2003-10-19 CN CNB2003101011541A patent/CN1190233C/en not_active Expired - Lifetime
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102836392A (en) * | 2012-09-28 | 2012-12-26 | 云南名扬药业有限公司 | Liquid oral preparation for treating malignant tumor and preparation method |
| CN103263474A (en) * | 2013-04-16 | 2013-08-28 | 阚兆云 | Traditional Chinese medicine composition and preparation method thereof |
| CN104758822A (en) * | 2015-03-23 | 2015-07-08 | 陈泽林 | A traditional Chinese medicine composition for stomach cancer and a preparing method thereof |
| CN113209251A (en) * | 2021-05-27 | 2021-08-06 | 丁殿西 | Traditional Chinese medicine composition, preparation method and application of traditional Chinese medicine composition in preparation of antitumor drugs |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1190233C (en) | 2005-02-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101209297A (en) | Compound Chinese medicinal granule for treating chicken coccidiosis | |
| CN101850032B (en) | Anti-tumor traditional Chinese medicine composition and preparation method and application thereof | |
| CN1190233C (en) | Anti-neoplastic medicine and its preparation method | |
| CN101352560B (en) | Medicament for treating tumor | |
| CN105999096A (en) | Composition for enhancing immunity and application | |
| CN1895220A (en) | 20(R)-ginseng sapoglycoside Rg3 medicinal soluble intermediate and its production | |
| CN1169839C (en) | Wolfberry polysaccharide and its prepn. and application | |
| CN1259054C (en) | Application of gentiopicrin in preparing medication for restraining hepatitis B virus | |
| CN101352559B (en) | Medicinal preparation for treating tumer | |
| CN1197615C (en) | Antineoplastic medicine and its preparation process | |
| CN110092806B (en) | Analgesic C of aconite19Diterpene alkaloid glucoside and application thereof | |
| CN1247223C (en) | Greater celandine extract and its preparation method and application | |
| CN1094052C (en) | Anticancer goose blood preparation | |
| CN1723956A (en) | Medicine for treating chronic gastritis and gastric carcinoma, and its prepn. method | |
| CN1836684A (en) | Silktree albizzia general saponin and its extraction method, pharmaceutical use of the said composition and medicine preparation | |
| KR100485936B1 (en) | Anticarcinogenic constituents of ginsenoside Rh2 and Rg3 | |
| CN104257955A (en) | Anti-hepatoma traditional Chinese medicine mixture containing arisaema amurense and production method of anti-hepatoma traditional Chinese medicine mixture | |
| CN103919819A (en) | Poria cocos natural composition and anti-cancer vomit-preventing application thereof | |
| CN1834108B (en) | Acanthopanax giraldii Harms compound polysaccharide, preparation technique, uses and its compound polysaccharide composition | |
| CN1823884A (en) | Preparation method of aidi injection agent | |
| CN1500505A (en) | Medication composition for children 's virus pneumonia and its preparation method | |
| CN107362158A (en) | Purposes of the Strychnos nux-vomica aglycon in antineoplastic is prepared | |
| CN1927366A (en) | Traditional Chinese medicine composition for treating chronic enterogastritis | |
| CN1308017C (en) | Medicine composition for treating eliminateion, dysentery and eruptive disease | |
| CN102614162B (en) | Application of gingerol and cerous oxalate composition to preparation of toxicity-decreasing and efficacy-increasing drugs for cancer chemotherapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: YUNNAN MINGYANG PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: WEN XIANMIN Effective date: 20111214 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 650011 KUNMING, YUNNAN PROVINCE TO: 650051 KUNMING, YUNNAN PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20111214 Address after: 650051 first floor, No. 297, Qingnian Road, Yunnan, Kunming Patentee after: Yunnan Sunsail Pharmaceutical Co.,Ltd. Address before: 650011, Dongfeng East Road, Panlong District, Yunnan, Kunming 14 Patentee before: Wen Xianmin |
|
| CX01 | Expiry of patent term |
Granted publication date: 20050223 |
|
| CX01 | Expiry of patent term |